Telomir Pharmaceuticals, Inc. has entered into a binding Letter of Intent with TELI Pharmaceuticals, Inc. to acquire all outstanding shares of TELI through a stock-for-stock exchange. The agreement will consolidate worldwide intellectual property and development rights for Telomir-1, an oral epigenetic therapy in preclinical development for cancer, aging, and age-related diseases. The exchange ratio for the shares will be determined by an independent third-party valuation. Certain TELI shareholders have committed up to $5 million in cash contributions to support the transaction and future development, with milestone-based payments tied to regulatory and clinical progress for Telomir-1. The agreement includes a six-month lockup period for the shares to be issued and unifies global rights to streamline development and partnership activities. Completion remains subject to due diligence, approvals, and execution of definitive agreements.